Kainos Medicine's HIV drug cleared for marketing in China

South Korea’s Kainos Medicine said on Monday its investigational HIV treatment out-licensed to China’s Jiangsu Aidea Pharmaceuticals has received marketing approval from Chinese health authorities.

Jiangsu Aidea Pharmaceuticals introduced KM023 in 2014 after a Phase 1 clinical trial and has developed it under the project name of ACC007. The drug was evaluated in combination with tenofovir (TDF) and lamivudine (3TC) in a Phase 3 clinical trial which was completed last year.

ACC007 is expected to take a high market share after launching as the first oral HIV treatment commercialized in China.

Kainos Medicine said it is eligible to receive royalties on sales of the drug from Jiangsu Aidea Pharmaceuticals. Sales will continue to increase in the future as the AIDS care market is on a high growth curve in China and the Chinese government is seeking medical support to Brazil and South Africa, Kainos Medicine added.

Kainos Medicine is also preparing to make inroads into emerging markets through a joint venture with Jiangsu Aidea Pharmaceuticals.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]